Glaser CM, Millesi W, Kornek GV, Long S, Schull B, Watzinger F, Selzer E, Lavey RS Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705-715

Abstract:

We assessed the influence of hemoglobin level and r-HuEPO administration on response to chemoradiotherapy, locoregional tumor control, and overall survival in patients treated with neoadjuvant chemoradiotherapy and surgery for a squamous cell carcinoma of the oral cavity or oropharynx.
The 191 study patients were treated with mitomycin C (15 mg/m(2) day 1), 5-fluorouracil (750 mg/m(2)/day, days 1-5), and radiotherapy (50 Gy in 25 fractions weeks 1-5), followed by resection of the primary tumor bed and neck dissection at the General Hospital Vienna, Austria, between November 1989 and October 1998 for a T2-4, N0-3, M0 SCC of the oral cavity or oropharynx. Starting in May 1996, patients with a low hemoglobin (Hgb) before or during chemoradiotherapy received r-HuEPO 10,000 IU/kg s.c. 3-6 times/week until the week of surgery.
On multivariate analysis, Hgb level and use of r-HuEPO were independent prognostic factors for response to chemoradiotherapy and locoregional tumor control (p < 0.01). Pathologic response to neoadjuvant therapy was also predictive of locoregional control (p < 0.001). Patients with a pretreatment Hgb > or = 14.5 g/dL had significantly higher complete response, locoregional control, and survival rates than the patients with a pretreatment Hgb < 14.5 g/dL who did not receive r-HuEPO (p < 0.05). The response, control, and survival rates in patients with a pretreatment Hgb < 14.5 g/dL given r-HuEPO were significantly higher than in low Hgb patients not given r-HuEPO (p < or = 0.001) and equivalent to patients with a pretreatment Hgb > 14.5 g/dL (p > or = 0.3).
Low pretreatment Hgb is a negative prognostic factor for oral cavity and oropharyngeal SCCA patients, but was completely abrogated by r-HuEpo administration during neoadjuvant chemoradiotherapy. Randomized trials of radiation and/or chemotherapy with or without r-HuEPO for patients whose Hgb level is either low at the start of therapy or is anticipated to become low during therapy are indicated.

Glaser CM, Millesi W, Kornek GV, Long S, Schull B, Watzinger F, Selzer E, Lavey RSImpact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705-715 | Request PDF. Available from: https://www.researchgate.net/publication/11944684_Glaser_CM_Millesi_W_Kornek_GV_Long_S_Schull_B_Watzinger_F_Selzer_E_Lavey_RSImpact_of_hemoglobin_level_and_use_of_recombinant_erythropoietin_on_efficacy_of_preoperative_chemoradiation_therapy_for_squam [accessed Oct 22 2018].

SPECT-CT for topographic mapping of sentinel lymph nodes prior to gamma probe-guided biopsy in head and neck squamous cell carcinoma.

J Craniomaxillofac Surg. 2004 Dec;32(6):343-9. SPECT-CT for topographic mapping of sentinel lymph nodes prior to gamma probe-guided biopsy in head and neck squamous cell carcinoma. Wagner A1, Schicho K, Glaser C, Zettinig G, Yerit K, Lang S, Klug C, Leitha T. Author information Abstract INTRODUCTION: Lymphoscintigraphic planar imaging is a common procedure for sentinel lymph […]

Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression, or cell proliferation?

Nucl Med Biol. 1998 Aug;25(6):539-41. Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression, or cell proliferation? Leitha T1, Glaser C, Lang S. Abstract A consensus has emerged that early imaging (within 20 min post-injection [p.i.] of sestamibi) has the highest diagnostic yield. Tc-99m-sestamibi uptake has been associated with P-glycoprotein-mediated multi-drug resistance […]

Technetium-99m-MIBI in primary and recurrent head and neck tumors: contribution of bone SPECT image fusion.

J Nucl Med. 1998 Jul;39(7):1166-71. Technetium-99m-MIBI in primary and recurrent head and neck tumors: contribution of bone SPECT image fusion. Leitha T1, Glaser C, Pruckmayer M, Rasse M, Millesi W, Lang S, Nasel C, Backfrieder W, Kainberger F. Abstract We prospectively investigated 200 patients with the clinical suspicion for head and neck tumors. The final diagnoses were 94 primary and 56 (37 confirmed, 19 […]

Mandibular pain as the leading clinical symptom for metastatic disease: nine cases and review of the literature.

Ann Oncol. 1998 May;9(5):559-64. Mandibular pain as the leading clinical symptom for metastatic disease: nine cases and review of the literature. Pruckmayer M1, Glaser C, Marosi C, Leitha T. University Clinics of Nuclear Medicine, University Vienna, Austria. Abstract BACKGROUND: Metastases to the jaws are a rare phenomenon. Nevertheless, the appearance of non-specific symptoms such as toothache can signal the […]

,

Clinical manifestations and diagnostic approach to metastatic cancer of the mandible.

Int J Oral Maxillofac Surg. 1997 Oct;26(5):365-8. Clinical manifestations and diagnostic approach to metastatic cancer of the mandible. Glaser C1, Lang S, Pruckmayer M, Millesi W, Rasse M, Marosi C, Leitha T. Author information Abstract In a 12-month period, metastatic cancer was diagnosed in eight patients. Six of them presented with pain mimicking toothache, temporomandibular […]

,

Horseshoe Le Fort I osteotomy in combination with endosteal

Int J Oral Maxillofac Surg. 1996 Dec;25(6):424-9. Horseshoe Le Fort I osteotomy in combination with endosteal implants–a median-term follow-up study. Watzinger F1, Ewers R, Millesi W, Kirsch A, Glaser C, Ackermann KL. Author information Abstract Fourteen patients with Class VI resorption of the maxilla were treated with horseshoe Le Fort I osteotomy. In 11 cases, […]